Renal Week 2009

RSS | Login | Register

Sections: Anemia | Hyperphosphatemia
Secondary Hyperparathyroidism | Transplantation
More: Videos

Anemia Coverage - Renal Week 2009

Weekly Low-Dose Iron May Reduce Overall Iron Use

Jody A. Charnow November 01, 2009

Smaller and more frequent IV iron dosing may result in a significant overall reduction in total iron use, according to a study presented at ASN's Renal Week 2009.

Why Large Doses of IV Iron Decrease HD Patient Survival Is Unclear

Jody A. Charnow November 01, 2009

Very large doses of IV iron are associated with decreased long-term survival in patients on hemodialysis, but a new analysis presented at ASN's Renal Week 2009 in San Diego probing this association could not establish a convincing reason for the increased mortality.

Anemia Hikes Long-Term Mortality in Non-Diabetic CKD Patients

Jody A. Charnow November 01, 2009

Anemia in non-diabetic CKD patients increases their risk of long-term mortality, and this predominantly explained by the association between anemia and degree of renal function, according to a study presented at ASN's Renal Week 2009.

Replacing HD Water Treatment Components Raises Hemoglobin Levels

Jody A. Charnow November 01, 2009

Preemptive replacement of hemodialysis (HD) water treatment components could result in significantly increased hemoglobin levels at lower doses of erythropoiesis-stimulating agents in HD patients, British researchers reported in a study presented at Renal Week 2009.

Wasting, Inflammation Hike Death Risk in Dialysis Patients with EPO Resistance

Jody A. Charnow October 31, 2009

Dialysis patients who have erythropoietin resistance also suffer from wasting, inflammation, or both, which increases their risk of death, according to researchers in The Netherlands who presented their study at Renal Week 2009.

Normal Phosphate Levels May Predict CKD Progression

Jody A. Charnow November 01, 2009

Serum phosphate within the normal range is a strong predictor of CKD progression, according to Italian researchers who presented a study at ASN's Renal Week 2009.

Tablet Burden Lowest with Lanthanum Carbonate

Jody A. Charnow November 01, 2009

CKD patients who used lanthanum carbonate to manage hyperphosphatemia had a lower mean tablet burden compared with those who took sevelamer hydrochloride or calcium acetate, according to researchers who presented a study at ASN's Renal Week 2009.

Hemodialysis Patients Benefit from Residual Kidney Function

Jody A. Charnow November 01, 2009

Hemodialysis patients who have residual kidney function have lower serum phosphate levels and use less phosphate binders than those without RKF, according to a study presented at ASN's Renal Week 2009.

Hyperphosphatemia Afflicts Nearly Three-Fourths of HD Patients

Jody A. Charnow November 01, 2009

Researchers who reviewed data from about 60,000 hemodialysis patients found that 73% of them experienced hyperphosphatemia according to a study presented at ASN's Renal Week 2009.

Nocturnal Hemodialysis Improves Protein and Phosphorus Status

Jody A. Charnow October 31, 2009

Patients who undergo in-center nocturnal hemodialysis have improved protein and phosphorus status compared with those treated with in-center conventional hemodialysis, according to a study that was presented at ASN's Renal Week 2009.

Researchers Link Elevated PTH to High Uric Acid

Eric Butterman November 01, 2009

Elevated serum parathyroid hormone levels are associated with higher serum uric acid levels in the U.S. adult population, investigators reported at ASN's Renal Week 2009.

Specialty Pharmacy Improves Control of Secondary Hyperparathyroidism

Eric Butterman November 01, 2009

Participation in a specialty pharmacy improved control of secondary hyperparathyroidism in hemodialysis patients, researchers reported at ASN's Renal Week 2009.

Cinacalcet Safely Treats Persistent Post-Kidney-Transplant Hyperparathyroidism

Eric Butterman November 01, 2009

Cinacalcet therapy is safe and effective for treating persistent hyperparathyroidism after renal transplantation, British researchers reported at ASN's Renal Week 2009. The medication is not associated with allograft dysfunction or significant adverse effects.

Elevated Parathyroid Hormone Linked to Obesity in CKD Patients

Eric Butterman November 01, 2009

Obesity in CKD patients is associated with increased parathyroid hormone levels independent of estimated glomerular filtration rate, according to a study presented at ASN's Renal Week 2009.

Ergocalciferol and Cholecalciferol Can Both Correct 25-Hydroxyvitamin D Deficiency

Jody A. Charnow October 31, 2009

Ergocalciferol 50,000 units per week and cholecalciferol 2,000 units per day can both correct 25-hydroxyvitamin D (25-OHD) deficiency within two months, but ergocalciferol recipients may achieve higher 25-OHD levels, according to researchers.

Diagnosing Acute Kidney Rejection through Urinary Proteome Analysis

John Schieszer November 01, 2009

It may be possible to detect acute allograft rejection in kidney transplant patients by urinary proteome analysis, according to a new German study that was presented at ASN's Renal Week 2009.

Risk Factors for New-Onset Diabetes in Pediatric Transplant Patients Identified

John Schieszer November 01, 2009

Among pediatric renal transplant recipients, increased age and having a very high or very low BMI, steroid use at the time of hospital discharge are three independent factors associated with an increased risk of new onset diabetes, according to new data presented at ASN's Renal Week 2009.

Intensified Dosing Regimen May Lower Rejection Rate

John Schieszer November 01, 2009

An intensified-dosing regimen of enteric-coated mycophenolate sodium in combination with basiliximab and standard doses of cyclosporine may result in a lower rate of rejection without compromising safety and tolerability, according to new data presented at ASN's Renal Week 2009.

High-Dose Multivitamin Does Not Reduce CVD Outcomes in Transplant Patients

John Schieszer November 01, 2009

Treatment of stable renal transplant recipients with a regimen of high-dose folic acid and vitamins B6 and B12 lowers total homocysteine levels better than a low-dose multivitamin containing no folic acid. However, it does not reduce cardiovascular disease outcomes or total mortality in this patient population, according to a study presented at ASN's Renal Week 2009.

Switching Immunosuppressants May Reduce Cancer Risk in Kidney Transplant Recipients

John Schieszer October 31, 2009

Switching to sirolimus from a calcineurin inhibitor may reduce the high risk of skin cancer after kidney transplantation, according to a new multi-centered trial conducted in Australia, New Zealand and the United States that was presented at ASN's Renal Week 2009.

Kamyar Kalantar-Zadeh, MD, PhD, MPH: Play

Stuart M. Sprague, DO: Play

Interview with Csaba P. Kovesdy, MD: Play

Interview with Editor Jody Charnow: Play

More

Renal Week Video

Kamyar Kalantar-Zadeh, MD, PhD, MPH: Play

Stuart M. Sprague, DO: Play

Interview with Csaba P. Kovesdy, MD: Play

Interview with Editor Jody Charnow: Play

More

Twitter Posts

Renal Nutrition Update

For the latest nutrition news and studies, click here to visit our Renal Nutrition Update dept.

Newsletters

Latest CME
Ongoing Clinical Trials
Conference Highlights
Expert Q&A
Weekly Round-Up

Legal Issues

Physician Sued For Failing to Follow Up

A primary care doctor referred a patient with an elevated PSA to a urologist. After a negative prostate biopsy, the doctor did not regularly conduct follow-up PSA testing, and the patient eventually died from prostate cancer.